Transcept Pharmaceuticals to Host Conference Call to Discuss Broadened Intermezzo Commercialization Strategy and New Consumer Advertising Campaign by Purdue PharmaCall Scheduled for Tuesday, November 27, 2012 at 8:30 a.m. ETPR Newswire
POINT RICHMOND, Calif., Nov. 26, 2012 /PRNewswire/ --Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced that it will host a conference call to discuss the broadened Intermezzo commercialization strategy and consumer advertising campaign by Purdue Pharmaceutical Products, L.P.
Conference Call InformationDate: Tuesday, November 27, 2012Time: 8:30 a.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537
A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until January 30, 2013.
About TransceptTranscept Pharmaceuticals, Inc.is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate) sublingual tablet C-IV is the firstFDAapproved Transcept product.PurduePharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Contact:Transcept Pharmaceuticals, Inc.Greg MannSr. Director, Corporate Communications(510) email@example.com
SOURCE Transcept Pharmaceuticals, Inc.